Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome.

Pharmaceutical research - 1 Jul 2014

Quiñones-Lombraña Adolfo, Ferguson Daniel, Hageman Blair Rachael, Kalabus James L, Redzematovic Almedina, Blanco Javier G

Abstract excerpt

PURPOSE: The intracardiac synthesis of anthracycline alcohol metabolites (e.g., daunorubicinol) contributes to the pathogenesis of anthracycline-related cardiotoxicity. Cancer patients with Down syndrome (DS) are at increased risk for anthracycline-related cardiotoxicity. We profiled the expression of anthracycline metabolizing enzymes in hearts from donors with- and without- DS. METHODS: Cardiac expression of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3-Hydroxysteroid Dehydrogenases
Share to Alcohol Oxidoreductases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aldehyde Reductase

Share to Anthracyclines

Share to Daunorubicin

Share to Down Syndrome

Share to Myocardium

Source

Open in PubMed Open full text

Identifiers

PMID: 24562808
DOI: 10.1007/s11095-013-1267-1
PMCID: PMC4065192

Genes

CBR1
CBR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome.PMID 24562808Read ↗

Expression of the anthracycline-metabolizing enzyme carbonyl reductase 1 in hearts from donors with Down syndrome.Semantic proximity Read ↗

Post-daunorubicin treatment effects on cardiovascular function in the Ts65Dn mouse model of Down syndromeSemantic proximity Read ↗

Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.Semantic proximity Read ↗

Risk factors for anthracycline-associated cardiotoxicity.Semantic proximity Read ↗

Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors.Semantic proximity Read ↗

A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factorSemantic proximity Read ↗

Cardiotoxicity and pharmacogenetics of doxorubicin in black Zimbabwean breast cancer patientsSemantic proximity Read ↗

Cardiotoxicity and pharmacogenetics of doxorubicin in black Zimbabwean breast cancer patients.Semantic proximity Read ↗

Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.Semantic proximity Read ↗

NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced CardiotoxicitySemantic proximity Read ↗

Drugs Metabolism-Related Genes Variants Impact on Anthracycline-Based Chemotherapy Induced Subclinical Cardiotoxicity in Breast Cancer PatientsSemantic proximity Read ↗

Unraveling the Genetic Blueprint of Doxorubicin-Induced Cardiotoxicity Through Systems Genetics ApproachesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.